Mylan Laboratories Appoints New Vice President of Human Resources
"We are delighted to have someone of Collette's calibre and background join our Company," said Robert J. Coury, Vice Chairman and CEO. "Her commitment to linking innovative people practices with sound business strategy will be a great asset to our organization as we continue to build our business and broaden our management team."
Ms. Taylor holds a Bachelor of Arts degree in psychology and sociology from Emory University and a Masters of Science degree with particular emphasis in industrial management from Loyola University Chicago. In addition, Ms. Taylor has a Juris Doctorate degree from Chicago Kent College of Law. She is a member of the Society for Human Resources Management, the Human Resources Management Association of Chicago, and a member of the Illinois Bar Association.
Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.
For more information about Mylan, visit www.mylan.com.
This press release includes statements that constitute "forward-looking statements", including with regard to building the Company's business, broadening the Company's management team and Ms. Taylor's affiliation with the Company. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties regarding market acceptance of and demand for the Company's products; the Company's dependence on third party suppliers and distributors for the raw materials the Company uses to manufacture its products; the effects of vigorous competition on commercial acceptance of the Company's products and their pricing; the Company's exposure to lawsuits and contingencies associated with its business; the possible negative effects of any interruption of manufacturing at the Company's production facility; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
CONTACT: Mylan Laboratories Inc. Kris King, 724-514-1800 SOURCE: Mylan Laboratories Inc.